Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

NCT02713204 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: REGN910-3
DRUG: Intravitreal Aflibercept Injection (IAI)

Sponsor

Regeneron Pharmaceuticals